TG Therapeutics, Inc. (TGTX) on GreekSoup https://greeksoup.ai/stocks/us/tgtx/ Every dated entry in the public record on TG Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Mon, 12 Oct 2026 00:00:00 +0000 TG Therapeutics, Inc.: short interest 30,634,421 shares at the 30 September 2026 settlement, 15.03 days to coverhttps://greeksoup.ai/stocks/us/tgtx/short-interest/us:TGTX:short-interest:2026-09-30:ff995916adWed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc.: short interest 30,153,733 shares at the 15 September 2026 settlement, 18.54 days to coverhttps://greeksoup.ai/stocks/us/tgtx/short-interest/us:TGTX:short-interest:2026-09-15:9e2f5c8162Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc.: Charney Laurence N (Director) sold 5,000 shares at $54.96 on 10 September 2026, $274,800https://greeksoup.ai/stocks/us/tgtx/insiders/us:TGTX:insider:2026-09-14:9e293994cdMon, 14 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc.: Form 144, Charney Laurence N plans to sell 5,000 shares worth $274,794 around 10 September 2026https://greeksoup.ai/stocks/us/tgtx/planned-sales/us:TGTX:planned-sale:2026-09-10:a09aa815a8Thu, 10 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc.: short interest 30,128,901 shares at the 31 August 2026 settlement, 15.86 days to coverhttps://greeksoup.ai/stocks/us/tgtx/short-interest/us:TGTX:short-interest:2026-08-31:58857a1235Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc.: short interest 30,109,741 shares at the 14 August 2026 settlement, 12.59 days to coverhttps://greeksoup.ai/stocks/us/tgtx/short-interest/us:TGTX:short-interest:2026-08-14:1a693c875cFri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc. Q2 FY2026 results: revenue $240 million, net income $8 millionhttps://greeksoup.ai/stocks/us/tgtx/results/fy2026-q2/us:TGTX:result:2026-08-05:46012990aaWed, 05 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc. filed 10-Q: form 10-qhttps://greeksoup.ai/stocks/us/tgtx/filings/us:TGTX:filing:2026-08-05:fe7f84e6bdWed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/tgtx/filings/us:TGTX:filing:2026-08-03:9253a83270Mon, 03 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc.: short interest 29,317,926 shares at the 31 July 2026 settlement, 13.62 days to coverhttps://greeksoup.ai/stocks/us/tgtx/short-interest/us:TGTX:short-interest:2026-07-31:6263526dd9Fri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> TG Therapeutics, Inc.: short interest 30,686,240 shares at the 15 July 2026 settlement, 15.45 days to coverhttps://greeksoup.ai/stocks/us/tgtx/short-interest/us:TGTX:short-interest:2026-07-15:c0b1cb45e7Wed, 15 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>